Relations and Predicates

Interest in the age-old problems of universals and individuation has received a new impetus from the current revival of ontology in the analytic tradition, the development of theories of individual properties (and the related application of mereological calculi to the analysis of predication), and the particular problems posed by relational predication and the nature of particulars. The essays explore aspects of the history of the issues and attempt to deal with the issues and with challenges to the distinctions that give rise to them. They continue the debates stemming from the revival of metaphysics rooted in Freges realism, the Austrian tradition of Brentano-Husserl-Meinong, and the early 20th century revolt against idealism embodied in writings of Moore and Russell and culminating in Wittgensteins Tractatus

Russell paradox, Russellian relations, and the problems of predication and impredicativity

1 online resource (PDF, page 63-87

O restituciji u Srbiji, februar 2014

This World Jewish Restitution Organization (WJRO) position paper reviews the current state of restitution in Serbia. It covers private property, Jewish communal property, heirless formerly-Jewish owned property, and Jewish cultural property that was confiscated or sold under duress during the Holocaust and/or subsequently nationalized under the communist regime in the area of the former Yugoslavia that is now Serbia. There is now an international consensus on the restitution of Holocaust-era property. Serbia and 46 other countries endorsed the Terezin Declaration on Holocaust Era Assets and Related Issues, establishing principles for property restitution. In 2010, 43 countries endorsed guidelines and based practices for immovable property restitution. Serbia participated with 38 other countries in November 2012 in the immovable property review conference, reaffirming its commitment to the ‘Terezin Declaration' and the ‘Guidelines and Best Practices'. In this paper, WJRO urges the government of Serbia to take steps to make further progress toward meeting the international consensus on restitution. WJRO urges the Government of Serbia to address the following important issues Communal property, Private property, Heirless property, Art, Judaica, and other cultural property.Ovo istraživanje se odnosi na process restitucije u Srbiji: privatnu imovinu Jevreja koja je oduzeta u periodu nakon Drugog svetskog rata, jevrejsku imovinu bez naslednika koja je oduzeta, brojnu imovinu koja je pripada jevrejskim zajednicama, kao i nepokretna imovina koja je bila oduzeta u toku Holokausta ili konfiskovana/nacionalizovana nakon Drugog svetskog rata. I pored posebnosti evropskih države u procesima podržavljavanja jevrejske imovine napravljen je konsenzus među evropskim državama koji se odnosi na imovinu oduzetu kao posledica Holokausta i u godinama nakon Drugog svetskog rata. Terezinska deklaracija koju je potpisala Srbija sa još 46 drugih zemalja je osnova za povraćaj imovine oduzete za vreme Holokausta ali i druga pitanja koja su u vezi sa tim. Srbija je sa 38 drugih zemalja učestvovala na sastanku novembra 2012. Uvidom u sadašnje stanje Srbiji WJRO (Svetska Jevrejska Ogranizacija za Restituciju) se obraća Vladi Srbije i drugim važnim državnim institucijama da obezbede što skorije rešavanje ovih pitanja koja se odnose na komunalnu jevrejsku imovinu, privatnu imovinu, imovinu bez naslednika kao i drugu nepokretnu imovinu, umetnine, Judaiku i kulturno blago

Against the Compositional View of Facts

It is commonly assumed that facts would be complex entities made out of particulars and universals. This thesis, which I call Compositionalism, holds that parthood may be construed broadly enough so that the relation that holds between a fact and the entities it ‘ties’ together counts as a kind of parthood. I argue firstly that Compositionalism is incompatible with the possibility of certain kinds of fact and universal, and, secondly, that such facts and universals are possible. I conclude that Compositionalism is false. What all these kinds of fact and universal have in common is a violation of supplementation principles governing any relation that may be intelligibly regarded as a kind of parthood. Although my arguments apply to Compositionalism generally, I focus on recent work by David Armstrong, who is a prominent and explicit Compositionalist

The Possibility Principle And The Truthmakers For Modal Truths

A necessary part of David Armstrong’s account of truthmakers for modal truths is his Possibility principle: any truthmaker for a contingent truth is also a truthmaker for the possibility of the complement of that contingent truth (if T makes p true and p is contingent, then T makes }*p true). I criticize Armstrong’s Possibility principle for two reasons. First, his argument for the Possibility principle both relies on an unwarranted generalization and vitiates his desire for relevant truthmakers. His argument undercuts relevant truthmakers by entailing that each contingent being is a truthmaker for all modal truths. Second, even if the argument seems successful, the Possibility principle is subject to counterexamples. Armstrong’s being composed of more than fifty atoms makes it true that something composed of more than fifty atoms exists and that truth is contingent, but his being composed of more than fifty atoms does not make it true that it is possible that it is not the case that something composed of more than fifty atoms exists

Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

<p>Abstract</p> <p>Background</p> <p>Canakinumab is a fully human anti-interleukin IL-1beta monoclonal antibody, being investigated for the treatment of rheumatoid arthritis (RA). This multicenter, phase II, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study investigated the efficacy and safety of canakinumab in patients with active RA despite ongoing therapy at stable doses of methotrexate.</p> <p>Methods</p> <p>Patients were randomized to receive one of four regimens, in addition to methotrexate, for 12 weeks: canakinumab 150 mg subcutaneously (SC) every 4 weeks (q4wk), canakinumab 300 mg SC (2 injections of 150 mg SC) every 2 weeks, a 600 mg intravenous loading dose of canakinumab followed by 300 mg SC every 2 weeks', or placebo SC every 2 weeks.</p> <p>Results</p> <p>Among 274 patients with evaluable efficacy data, the percentage of responders according to American College of Rheumatology 50 criteria (the primary endpoint, based on a 28-joint count) was significantly higher with canakinumab 150 mg SC q4wk than with placebo (26.5% vs. 11.4%, respectively; p = 0.028). Compared to placebo, this dosage of canakinumab was also associated with significantly more favorable responses at week 12 with respect to secondary endpoints including the Disease Activity Score 28, scores on the Health Assessment Questionnaire and Functional Assessment of Chronic Illness Therapy-Fatigue, swollen 28-joint count, and patient's and physician's global assessments of disease activity. No safety concerns were raised with canakinumab therapy, particularly with regard to infections. Few injection-site reactions occurred.</p> <p>Conclusion</p> <p>The addition of canakinumab 150 mg SC q4wk improves therapeutic responses among patients who have active RA despite stable treatment with methotrexate.</p> <p>Trial Registration</p> <p>(ClinicalTrials.gov identifier: <a href="http://www.clinicaltrials.gov/ct2/show/NCT00784628">NCT00784628</a>)</p

Etoricoxib - preemptive and postoperative analgesia (EPPA) in patients with laparotomy or thoracotomy - design and protocols

<p>Abstract</p> <p>Background and Objective</p> <p>Our objective was to report on the design and essentials of the <it>Etoricoxib </it>protocol<it>- Preemptive and Postoperative Analgesia (EPPA) </it>Trial, investigating whether preemptive analgesia with cox-2 inhibitors is more efficacious than placebo in patients who receive either laparotomy or thoracotomy.</p> <p>Design and Methods</p> <p>The study is a 2 × 2 factorial armed, double blinded, bicentric, randomised placebo-controlled trial comparing (a) etoricoxib and (b) placebo in a pre- and postoperative setting. The total observation period is 6 months. According to a power analysis, 120 patients scheduled for abdominal or thoracic surgery will randomly be allocated to either the preemptive or the postoperative treatment group. These two groups are each divided into two arms. Preemptive group patients receive etoricoxib prior to surgery and either etoricoxib again or placebo postoperatively. Postoperative group patients receive placebo prior to surgery and either placebo again or etoricoxib after surgery (2 × 2 factorial study design). The Main Outcome Measure is the cumulative use of morphine within the first 48 hours after surgery (measured by patient controlled analgesia PCA). Secondary outcome parameters include a broad range of tests including sensoric perception and genetic polymorphisms.</p> <p>Discussion</p> <p>The results of this study will provide information on the analgesic effectiveness of etoricoxib in preemptive analgesia and will give hints on possible preventive effects of persistent pain.</p> <p>Trial registration</p> <p>NCT00716833</p

Rheumatoid arthritis - treatment: 180. Utility of Body Weight Classified Low-Dose Leflunomide in Japanese Rheumatoid Arthritis

Background: In Japan, more than 20 rheumatoid arthritis (RA) patients died of interstitial pneumonia (IP) caused by leflunomide (LEF) were reported, but many of them were considered as the victims of opportunistic infection currently. In this paper, efficacy and safety of low-dose LEF classified by body weight (BW) were studied. Methods: Fifty-nine RA patients were started to administrate LEF from July 2007 to July 2009. Among them, 25 patients were excluded because of the combination with tacrolimus, and medication modification within 3 months before LEF. Remaining 34 RA patients administered 20 to 50 mg/week of LEF were followed up for 1 year and enrolled in this study. Dose of LEF was classified by BW (50 mg/week for over 50 kg, 40 mg/week for 40 to 50 kg and 20 to 30 mg/week for under 40 kg). The average age and RA duration of enrolled patients were 55.5 years old and 10.2 years. Prednisolone (PSL), methotrexate (MTX) and etanercept were used in 23, 28 and 2 patients, respectively. In case of insufficient response or adverse effect, dosage change or discontinuance of LEF were considered. Failure was defined as dosages up of PSL and MTX, or dosages down or discontinuance of LEF. Last observation carried forward method was used for the evaluation of failed patients at 1 year. Results: At 1 year after LEF start, good/ moderate/ no response assessed by the European League Against Rheumatism (EULAR) response criteria using Disease Activity Score, including a 28-joint count (DAS28)-C reactive protein (CRP) were showed in 14/ 10/ 10 patients, respectively. The dosage changes of LEF at 1 year were dosage up: 10, same dosage: 5, dosage down: 8 and discontinuance: 11 patients. The survival rate of patients in this study was 23.5% (24 patients failed) but actual LEF continuous rate was 67.6% (11 patients discontinued) at 1 year. The major reason of failure was liver dysfunction, and pneumocystis pneumonia was occurred in 1 patient resulted in full recovery. One patient died of sepsis caused by decubitus ulcer infection. DAS28-CRP score was decreased from 3.9 to 2.7 significantly. Although CRP was decreased from 1.50 to 0.93 mg/dl, it wasn't significant. Matrix metalloproteinase (MMP)-3 was decreased from 220.0 to 174.2 ng/ml significantly. Glutamate pyruvate transaminase (GPT) was increased from 19 to 35 U/l and number of leukocyte was decreased from 7832 to 6271 significantly. DAS28-CRP, CRP, and MMP-3 were improved significantly with MTX, although they weren't without MTX. Increase of GPT and leukopenia were seen significantly with MTX, although they weren't without MTX. Conclusions: It was reported that the risks of IP caused by LEF in Japanese RA patients were past IP history, loading dose administration and low BW. Addition of low-dose LEF is a potent safe alternative for the patients showing unsatisfactory response to current medicines, but need to pay attention for liver function and infection caused by leukopenia, especially with MTX. Disclosure statement: The authors have declared no conflicts of interes